Keymed Biosciences’ Stapokibart Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Study
China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that its IL-4Rα monoclonal antibody...
Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China
Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering...
Pfizer’s Gene Therapy Beqvez Wins FDA Nod for Moderate-to-Severe Hemophilia B
The US Food and Drug Administration (FDA) has granted marketing authorization to Pfizer (NYSE: PFE)...
Bio-Thera Solutions’ BAT1806 Receives Positive CHMP Recommendation for EU Approval
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...
HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...
China Launches Unannounced Inspections on Medical Insurance Funds, Targets Fraud and Mismanagement
The National Healthcare Security Administration (NHSA), National Health Commission (NHC), along with two other bureaus,...
Novartis’s Iptacopan (Fabhalta) Receives Marketing Approval in China for PNH Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received marketing approval from China for its iptacopan...
Mindray Bio-Medical Electronics Reports 15.04% YOY Revenue Growth in 2023 Financial Results
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for 2023,...
United Imaging Healthcare Reports 23.52% YOY Revenue Growth in 2023, Driven by Strong Product Launches and Partnerships
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year...
AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial
AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing...
Former Sinopharm Executive Yang Xiaoming Removed from National People’s Congress Over Alleged Serious Violations
Yang Xiaoming, previously the chief engineer and chief scientist of China National Pharmaceutical Group Corporation...
Neusoft Medical Systems Partners with West China Hospital to Boost Indigenous Medical Tech Innovation
China-based Neusoft Medical Systems Co., Ltd has entered into a strategic partnership with West China...
AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China
Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received...
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...
AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results...
MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion
China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off,...
Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million
Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable...
Wuhan Bio-Raid Biotechnology Secures NMPA Approval for First-in-Class CD99-Targeted CAR-T Therapy
Wuhan Bio-Raid Biotechnology Co., Ltd, a leading developer of chimeric antigen receptor (CAR)-T cell therapies...
Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its...
JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva
China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching...